We are live on
!
Find out more
Axsome Therapeutics
AXSM
AXSM
17 hedge funds and large institutions have $44.9M invested in Axsome Therapeutics in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
55% more funds holding
Funds holding: 11 → 17 (+6)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
6% less capital invested
Capital invested by funds: $47.7M → $44.9M (-$2.71M)
Holders
17
Holders Change
+6
Holders Change %
+54.55%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.91M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$316K |
| 3 |
JP Morgan Chase
New York
|
+$287K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$122K |
| 5 |
Morgan Stanley
New York
|
+$117K |
Top Sellers
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.02M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$671K |
| 3 |
Millennium Management
New York
|
-$517K |
| 4 |
Goldman Sachs
New York
|
-$226K |
| 5 |
Bank of New York Mellon
New York
|
-$107K |
